… This study seeks to investigate the impact of BCR-ABL tyrosine kinase inhibitors (imatinib,
nilotinib, AT-9283, and ZM-306416) on the proliferation of human malignant melanoma A375P …

… of nilotinib, a dual SRC/ABL inhibitor … , nilotinib, dasatinib, and bosutinib. In different
trials, ponatinib showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 …

… Nilotinib (formerly AMN107) is an orally bioavailable drug that is structurally related to …
in superior potency and selectivity for BCR-ABL [86]. Nilotinib has been used successfully in …

… HMC-1.2, low concentrations of the TKIs Nilotinib and Ponatinib resulted in enhanced
proliferation, … mutants of the tyrosine kinases KIT or BCR-ABL can be efficiently bypassed by a low-…

… Citation89 In vitro and ex vivo studies have shown that several TKIs (eg imatinib, nilotinib
and dasatinib), while inhibiting BCR-ABL1, lead to paradoxical activation of RAF, MEK and …

… Therefore, 26 patients (11 women and 15 men), who continued nilotinib treatment for 2 years
and had data for nilotinib C trough values at 3, 6, 12, and 24 months, were analyzed in this …

… Nejčastější příčinou rezistence jsou bodové mutace v genu BCR ABL1, méně pak i další na
… Nilotinib inhibited wild-type BCR-ABL kinase in CML derived and transfected cells, and also …

… Nilotinib is 30 times more potent at inhibiting BCR–ABL activity.Nilotinib could reduce the
BCR-ABL … At the end of 6 months, the median RQPCR for BCR ABL1 (IS) is shown in table no 6…

… nilotinib demonstrated a higher efficacy compared to imatinib in terms of achieving early
molecular responses (EMR), defined as BCR-ABL1 … toxicities related to nilotinib is of significant …

… of higher mRNA level after 9 months of nilotinib treatment. Very recent data have confirmed
the … of PTPRG significantly improved the response to nilotinib and decreased its IC 50 [135]. …